Materiały źródłowe

• #1 Chronic Lymphocytic Leukemia – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK470433/

  Chronic lymphocytic leukemia is a chronic lymphoproliferative disorder characterized by monoclonal B cell proliferation. It is the most common adult leukemia in Western populations and comprises 25 to 30 percent of leukemias in the United States. […] CLL comprises 25 to 30% of total leukemias in the United States. According to the American Cancer Society, there will be approximately 21,040 new CLL cases and about 4,060 deaths in the year of 2020. Worldwide, 191,000 cases and 61,000 deaths are attributed to CLL/SLL every year. CLL can affect adults as young as 30 years of age. However, it is mostly seen in adults with an average age of 70 years. CLL is extremely rare in children. The incidence is known to rapidly increase with increasing age. CLL has a slightly higher incidence in male populations than female populations (1.3 to 1 to 1.7 to 1). However, studies have shown that women can have a more aggressive form of the disease than men.

• #2 Chronic Lymphocytic Leukemia (CLL): Practice Essentials, Pathophysiology, Etiology

  https://emedicine.medscape.com/article/199313-overview

  Chronic lymphocytic leukemia (CLL) is the most common form of leukemia found in adults in Western countries. […] The American Cancer Society estimates that 18,740 new cases of CLL will be diagnosed in the United States in 2023. […] The true incidence in the US is unknown and is likely higher, as estimates of CLL incidence come from tumor registries, and many cases are not reported. […] Although the incidence of CLL has been stable over the last two decades, mortality has been steadily declining. […] Although the incidence of CLL in Western countries is similar to that of the United States, CLL is extremely rare in Asian countries (eg, China, Japan), where it is estimated to comprise only 10% of all leukemias. […] The incidence of CLL is higher in Whites than in Blacks. […] The incidence of CLL is higher in males than in females, with a male-to-female ratio of 1.9:1. […] CLL is a disease that primarily affects the elderly, with the median age at diagnosis being 70 years. […] In familial CLL (ie, disease in patients with at least one first-degree relative with CLL), median age at diagnosis is 57 years.

• #3 Key Statistics for CLL | American Cancer Society

  https://www.cancer.org/cancer/types/chronic-lymphocytic-leukemia/about/key-statistics.html

  The American Cancer Society’s estimates for chronic lymphocytic leukemia (CLL) in the United States for 2025 are: […] About 23,690 new cases of CLL […] About 4,460 deaths from CLL. […] CLL accounts for about 1 in 3 new cases of leukemia in the US, and about 1% of cancers overall. […] CLL is slightly more common among men than women, but the average lifetime risk of getting CLL for both sexes is about of 1%. […] CLL mainly affects older adults. The average age of people when they are diagnosed is around 70 years. It’s rarely seen in people under age 40, and it’s extremely rare in children.

• #4 Chronic Lymphocytic Leukemia — Cancer Stat Facts

  https://seer.cancer.gov/statfacts/html/clyl.html

  Estimated New Cases in 2025 23,690 […] Estimated Deaths in 2025 4,460 […] Chronic lymphocytic leukemia represents 1.2% of all new cancer cases in the U.S. […] In 2025, it is estimated that there will be 23,690 new cases of chronic lymphocytic leukemia and an estimated 4,460 people will die of this disease. […] The rate of new cases of chronic lymphocytic leukemia was 4.7 per 100,000 men and women per year based on 20182022 cases, age-adjusted. […] Death rates from chronic lymphocytic leukemia are higher among older adults, or those 75 and older. […] The death rate was 1.1 per 100,000 men and women per year based on 20192023 deaths, age-adjusted. […] The percent of chronic lymphocytic leukemia deaths is highest among people aged 85+. […] Keeping track of new cases, deaths, and survival over time (trends) can help scientists understand whether progress is being made and where additional research is needed to address challenges, such as improving screening or finding better treatments. […] Using statistical models for analysis, age-adjusted rates for new chronic lymphocytic leukemia cases have been falling on average 0.9% each year over 20132022. Age-adjusted death rates have been falling on average 1.9% each year over 20142023.

• #5 Chronic lymphocytic leukemia – Wikipedia

  https://en.wikipedia.org/wiki/Chronic_lymphocytic_leukemia

  CLL is the most common type of leukemia in the Western world compared to non-Western regions such as Asia, Latin America, and Africa. […] It is observed globally that males are twice as likely than females to acquire CLL. […] CLL is primarily a disease of older adults, with 9 out of 10 cases occurring after the age of 50 years. […] The median age of diagnosis is 70 years. […] According to the American Cancer Society, they estimate that there will about 23,690 new cases of CLL with about 4,460 deaths from CLL in the United States throughout 2025. […] Five-year survival following diagnosis is approximately 83% in the United States. […] Because of the prolonged survival, which was typically about 10 years in past decades, but which can extend to a normal life expectancy, the prevalence (number of people living with the disease) is much higher than the incidence (new diagnoses).

• #5 Chronic lymphocytic leukemia – Wikipedia

  https://en.wikipedia.org/wiki/Chronic_lymphocytic_leukemia

  CLL is the most common type of leukemia in the UK, accounting for 38% of all leukemia cases. […] In Western populations, subclinical „disease” can be identified in 3.5% of normal adults, and in up to 8% of individuals over the age of 70. […] In contrast, CLL is rare in Asian countries, such as Japan, China, and Korea, accounting for less than 10% of all leukemias in those regions. […] People who live near areas with considerable industrial pollution have an elevated risk of developing leukemia, particularly CLL.

• #6 Key Statistics for Chronic Lymphocytic Leukemia

  https://www.healthline.com/health/cll/statistics-and-facts

  CLL is most common in non-Hispanic white males. In studies exploring the demographics of CLL in the United States, roughly 90% of cases occur in white people. […] Among both males and females, the rate of new CLL cases is higher in non-Hispanic white Americans than any other racial or ethnic group. […] According to the National Cancer Institute, CLL occurs at a rate of 7.8 per 100,000 white males and 4.1 per 100,000 white females. […] According to a 2022 study, Black Americans are about 64% more likely to have shorter survival with CLL than white Americans. […] Researchers found the median survival in white people with CLL was 9.14 years after diagnosis compared with 7.0 years in Black people. […] Males have a slightly higher risk of getting CLL than females. Overall, the rate of CLL is 6.3 per 100,000 males and 3.3 per 100,000 females.

• #7 Chronic Lymphocytic Leukemia Market Size, Share, Report 2034

  https://www.imarcgroup.com/chronic-lymphocytic-leukemia-market

  As per the National Cancer Institute, chronic lymphocytic leukemia affects 7.8 per 100,000 white men and 4.1 per 100,000 white women. […] Epidemiological studies have indicated that the frequency of chronic lymphocytic leukemia increases exponentially with age, peaking in the elderly. […] Males are approximately twice as likely to develop chronic lymphocytic leukemia as females. […] In India, the incidence rate of chronic lymphocytic leukemia is 0.41 per 100,000 people, which is ten times lower than in the United States. […] The average lifetime chance of developing chronic lymphocytic leukemia is around 1 in 175 (0.57%).

• #8 Chronic lymphocytic leukaemia (CLL) statistics | Cancer Research UK

  https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/leukaemia-cll

  There are around 4,000 new chronic lymphocytic leukaemia cases in the UK every year, that’s 11 every day (2017-2019). […] Chronic lymphocytic leukaemia accounted for 1% of all new cancer cases in the UK in 2017-2019. […] In females in the UK, chronic lymphocytic leukaemia accounted for around 1,500 new cancer cases every year (2017-2019). […] In males in the UK, chronic lymphocytic leukaemia accounted for around 2,500 new cancer cases every year (2017-2019). […] Incidence rates for chronic lymphocytic leukaemia in the UK are highest in people aged 85 to 89 (2017-2019). […] Each year around 4 in 10 (41%) of all new chronic lymphocytic leukaemia cases in the UK are diagnosed in people aged 75 and over (2017-2019). […] Since the early 1990s, chronic lymphocytic leukaemia incidence rates have increased by almost a sixth (16%) in the UK. Rates in females have increased by a seventh (14%), and rates in males have increased by around a tenth (9%) (2017-2019).

• #9 The global burden and attributable risk factors of chronic lymphocytic leukemia in 204 countries and territories from 1990 to 2019: analysis based on the global burden of disease study 2019 | BioMedical Engineering OnLine | Full Text

  https://biomedical-engineering-online.biomedcentral.com/articles/10.1186/s12938-021-00973-6

  Epidemiological studies found that the incidence of CLL rises exponentially with age and reaches a peak in elderly populations. The incidence of CLL is approximately 2 times higher in males than that in females. […] Despite of promising results in emerging targeted medications including BCL-2 inhibitor venetoclax and Bruton tyrosine kinase (BTK) inhibitors represented by ibrutinib and zanubrutinib, it cannot be neglected that the high-cost treatment and accompanied severe adverse events contributed to a heavy global burden to CLL patients. […] The GBD study 2019 assessed epidemiologic data about 369 diseases across 204 countries and territories and provided an unprecedented opportunity to understand the trends in the global burden of CLL. […] To our best knowledge, this study is the first study to provide a comprehensive description of the epidemiology and global burden of CLL worldwide.

• #9 The global burden and attributable risk factors of chronic lymphocytic leukemia in 204 countries and territories from 1990 to 2019: analysis based on the global burden of disease study 2019 | BioMedical Engineering OnLine | Full Text

  https://biomedical-engineering-online.biomedcentral.com/articles/10.1186/s12938-021-00973-6

  Chronic lymphocytic leukemia (CLL) is the most prevalent subtype of leukemia in Western countries, causing a substantial health burden on patients and society. Comprehensive evaluation of the epidemiological characteristics of CLL is warranted, especially in the current context of global population aging. The main objective of this study is evaluating the disease burden of CLL at global, regional, and national levels from 1990 to 2019. […] The global burden of CLL has increased dramatically. A high incidence has been achieved in males and elder people. Countries and territories with high social-demographic index (SDI) tended to have higher global burden than low-SDI region. Of risk factors, high body mass index and smoking were the major contributors for CLL-related mortality and disability adjusted life-years (DALYs).

• #10 Chronic Lymphocytic Leukemia – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK470433/

  The incidence of CLL varies by geographic location and race. CLL is most commonly seen in adults of the Western population. It is high amongst the Caucasian population compared to the Asian Pacific Islanders or the African-American population. The incidence of CLL in Western countries is similar to that of the United States but is rarely seen in Asian countries (China and Japan). CLL is common amongst the Jews of Eastern European descent. It is most commonly seen in Non-Hispanic Whites and least common in Asians. The incidence in African Americans is in between the Caucasian and the Asian ethnicity groups. […] CLL is reported to have a genetic basis and is known to run in families (familial CLL). The age at diagnosis of the second-generation offspring is nearly 20 years younger as compared to the parent. First-degree relatives (siblings, children, or parents) of CLL patients have double the risk for CLL. Moreover, 17% of first-degree family members of CLL patients had monoclonal B cell lymphocytosis, which is a precursor of CLL. Ultimately only a small percentage of patients with monoclonal B-cell lymphocytosis (MBL) will develop into CLL.

• #11 Epidemiology and ethnic aspects of B cell chronic lymphocytic leukemia in Israel | Leukemia

  https://www.nature.com/articles/2401140

  Chronic lymphocytic leukemia (CLL) represents 30% of all leukemias in Caucasians. In East Europe and USA the disease incidence is high while in Asia and Africa CLL is rare. The results of this study show a high incidence of CLL in Israel. The mean annual age-adjusted incidence 4.3 per 100000 person-year is among the highest reported values. Our study confirms previous data on the prevalence of CLL in Ashkenazi compared to Sephardic Jews. The rise in CLL rate in the reviewed period occurred in both populations, mainly in the Sephardic group. The relative risk for Ashkenazies compared to Sephardics decreased from 6.0 in the 19751979 period to 2.4 in 19901996. A high rate of CLL was found in new immigrants from the former USSR with 26 cases de novo diagnosed and 11 prevalent cases not included in this series among approximately 60000 new immigrants in the area over the last 8 years. Our findings suggest that ethnic origin of the patients itself does not affect the biological and clinical behavior of this disease.

• #12 Chronic Lymphocytic Leukemia: Overview

  https://medical.lilly.com/us/diseases/disease-education-resources/oncology/hematological-malignancy/education-resources/chronic-lymphocytic-leukemia-overview

  CLL is the most common type of chronic leukemia characterized by aberrant proliferation of mature monoclonal B cells in the bone marrow. […] Recently reported age-adjusted incidence of 4.6 per 100,000 per year in the US population. […] In 2021, there were an estimated 215,107 people living with CLL in the United States. […] Median age at diagnosis is 70 years with incidence increasing with age. […] More common in men. […] Highest incidence in Caucasian population and Western countries. […] Genetic basis and can develop in families. First-degree relatives of patients with CLL have double the risk of CLL. […] Diagnosis of CLL is established by blood counts, blood smears, and immunophenotyping of circulating B lymphocytes. […] CLL is usually asymptomatic and discovered via routine blood tests.

• #13 Key Statistics for Chronic Lymphocytic Leukemia

  https://www.healthline.com/health/cll/statistics-and-facts

  In the United States, approximately 20,700 people develop CLL each year, reports the American Cancer Society. These cases account for just over 1% of new cancer diagnoses annually. Since 2010, the frequency of CLL in the United States has been declining. […] Although not very common overall, CLL is the most common form of leukemia in adults. Older adults are more likely to be affected than younger people: CLL is most frequently diagnosed in people between 65 and 74 years old. Less than 2% of new cases happen in people younger than age 45 years. CLL is rarely seen in children. […] In the United States, the likelihood that the average person will get CLL is about 1 in 175, or 0.57%. The likelihood of developing CLL is higher for people who: are older, are white, are male, have a history of exposure to certain chemicals, like Agent Orange or some pesticides, have radon exposure, have a first-degree relative with CLL.

• #14 Chronic lymphocytic leukaemia (CLL) statistics | Cancer Research UK

  https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/leukaemia-cll

  Over the last decade, chronic lymphocytic leukaemia incidence rates have decreased by around a twentieth (6%) in the UK. Rates in females have decreased by more than a twentieth (7%), and rates in males have decreased by more than a twentieth (7%) (2017-2019). […] There are around 980 chronic lymphocytic leukaemia deaths in the UK every year, that’s more than 2 every day (2017-2019). […] Chronic lymphocytic leukaemia accounts for less than 1% of all cancer deaths in the UK (2017-2019). […] In females in the UK, chronic lymphocytic leukaemia accounts for around 380 deaths every year (2017-2019). […] In males in the UK, chronic lymphocytic leukaemia accounts for around 590 deaths every year (2017-2019). […] Mortality rates for chronic lymphocytic leukaemia in the UK are highest in people aged 90+ (2017-2019).

• #15 Chronic lymphocytic leukaemia (CLL) statistics | Cancer Research UK

  https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/leukaemia-cll

  Each year around 8 in 10 of all chronic lymphocytic leukaemia deaths (79%) in the UK are in people aged 75 and over (2017-2019). […] Since the early 1970s, chronic lymphocytic leukaemia mortality rates have decreased by more than a fifth (22%) in the UK. Rates in females have decreased by a quarter (25%), and rates in males have decreased by around a quarter (26%) (2017-2019). […] Over the last decade, chronic lymphocytic leukaemia mortality rates have decreased by more than a quarter (28%) in the UK. Rates in females have decreased by more than a quarter (27%), and rates in males have decreased by almost a third (30%) (2017-2019).

• #16 Active surveillance for chronic lymphocytic leukemia | Canadian Cancer Society

  https://cancer.ca/en/cancer-information/cancer-types/chronic-lymphocytic-leukemia-cll/treatment/active-surveillance

  When you’re diagnosed with chronic lymphocytic leukemia (CLL), you may start with a type of treatment called active surveillance and not need to start active treatment right away. This is because CLL often grows slowly and may not cause problems at first. […] Active surveillance means that your healthcare team monitors the cancer closely for changes rather than giving treatment right away. […] Active surveillance helps avoid side effects that can happen with treatments like targeted therapy or chemoimmunotherapy. […] Active treatment starts when you develop symptoms or when there is disease progression. […] During active surveillance, your healthcare team uses tests and exams to check if CLL is progressing or your condition is getting worse. […] CLL weakens your immune system, which increases your risk for infections.

• #17 Leukemia and Other Blood Cancers: CLL Active Surveillance Program | Memorial Sloan Kettering Cancer Center

  https://www.mskcc.org/cancer-care/types/leukemias/types/chronic-lymphocytic-leukemia-cll/cll-active-surveillance

  After they learn they have CLL, only approximately 1 out of every 3 people need treatment right away. […] If you have CLL but do not have any symptoms or another problem caused by CLL such as low red blood cells, platelets, or growing lymph nodes, your doctor may recommend active surveillance. […] People with CLL may want to start treatment right away. But research has shown that early treatment for CLL does not help people live longer. […] Treatment has side effects and risks. While each patients case is different and your care team will make a personalized assessment for you, we may recommend you delay treatment if: You have no symptoms, CLL is not causing other problems with blood counts such as low red blood cell or platelet counts, Your lymph nodes or spleen are not at a size that need treatment.

• #18 https://www.lls.org/leukemia/chronic-lymphocytic-leukemia/treatment/watch-and-wait

  https://www.lls.org/leukemia/chronic-lymphocytic-leukemia/treatment/watch-and-wait

  Not all CLL patients need to start treatment immediately. Watch and wait is a valid treatment approach that means your doctor will watch your condition but not give you treatment unless you have signs or symptoms that appear or change. This approach includes: […] Many studies have compared the watch-and-wait approach to an early treatment approach for people with low-risk CLL. […] To date, clinical trials have not shown that there are any benefits of early treatment in terms of survival. […] Several studies have confirmed that patients with early-stage CLL do not benefit from the use of alkylating agents or aggressive chemotherapy, and these treatments do not prolong survival. […] There are risks of early treatment, including potential side effects and treatment complications. […] Patients may build up a resistance to the drugs used and would not be able to use them again when treatment for progressive disease is necessary. […] Some people with CLL can be managed with a watch-and-wait approach for years before the disease progresses. The decision to begin treatment is based on a patients symptoms, test results, and the stage of CLL.

• #19 Leukemia and Other Blood Cancers: CLL Active Surveillance Program | Memorial Sloan Kettering Cancer Center

  https://www.mskcc.org/cancer-care/types/leukemias/types/chronic-lymphocytic-leukemia-cll/cll-active-surveillance

  Chronic lymphocytic leukemia (CLL) is a type of cancer. White blood cells called lymphocytes (LIM-foh-sites) are cells that are part of our immune system that help the body fight off infection. Patients with CLL have too many abnormal lymphocytes. They may also have enlarged lymph nodes and spleens. CLL may develop more slowly than other types of leukemia. […] Led by our leukemia experts, MSK has a surveillance program just for people with chronic lymphocytic leukemia (CLL). Surveillance means to actively monitor. Its not the same as no treatment. […] Active surveillance for CLL is safe and is recommended for many patients. […] Many people with CLL do not have symptoms. They only need to be watched or monitored, which is called active surveillance (ser-VAY-lents). We closely watch the CLL but do not treat it unless we see signs its getting worse.

• #20 Chronic Lymphocytic Leukemia

  https://fpnotebook.com/HemeOnc/Leukemia/ChrncLymphcytcLkm.htm

  Most common Leukemia in the United States. […] Older patients […] Usually over age 50 years. […] Age over 65 years old in 70 to 85% of new cases. […] More common in men. […] Rare in Asian patients. […] Indications for observation only (no active treatment) […] Anemia absent AND […] Thrombocytopenia absent AND […] Fewer than 3 Lymph Node regions involved. […] Repeat history and physical exam every 6 to 12 months (evaluate for progression to active disease). […] Periodic Labs every 6 to 12 months […] Complete Blood Count (CBC with differential). […] Vaccination […] Influenza Vaccine yearly. […] Pneumococcal Vaccine every 5 years. […] Routine cancer screening (appropriate for age and gender). […] Periodic Echocardiogram (rest and stress) […] Frequency depends on risks and Echocardiogram findings.

• #21 Chronic lymphocytic leukemia | Radiology Reference Article | Radiopaedia.org

  https://radiopaedia.org/articles/chronic-lymphocytic-leukaemia?lang=us

  Chronic lymphocytic leukemia is considered the most common type of leukemia in the Western hemisphere; its prevalence in Europe and North America ranges from 29-38% of all leukaemias. It primarily affects adults 65-70 years of age. […] About one-third of patients with chronic lymphocytic leukemia will never require treatment.

• #22 Active monitoring in CLL | Blood Cancer UK

  https://bloodcancer.org.uk/understanding-blood-cancer/leukaemia/chronic-lymphocytic-leukaemia-cll/cll-active-monitoring/

  Because CLL is a slow-growing type of blood cancer, most people dont need treatment when theyre diagnosed, and may not need treatment for several years. […] Active monitoring involves regular check-ups which could be with your GP or at a hospital. Youll have blood tests to check your blood cell counts and general health, and you may have a physical examination to check for swollen lymph nodes (glands). […] Many people stay on watch and wait for several years. Some people never need treatment. […] Your hospital team will look for these things when considering if its time to start treatment: Rapidly increasing lymphocyte count, Anaemia, Low platelets, Swollen lymph nodes, Swollen spleen, „B” symptoms, Significant fatigue. […] None of these things is an automatic trigger for starting treatment, but they will influence decisions about when to start treatment.

• #23 Leukemia and Other Blood Cancers: CLL Active Surveillance Program | Memorial Sloan Kettering Cancer Center

  https://www.mskcc.org/cancer-care/types/leukemias/types/chronic-lymphocytic-leukemia-cll/cll-active-surveillance

  Our leukemia specialists, Dr. Meghan C. Thompson (left) and Dr. Prioty Islam (right), work with APP Kathleen Pormento Mendoza to develop a personalized plan for your active surveillance for CLL. […] People diagnosed with monoclonal B cell lymphocytosis (MBL) can also join our CLL Active Surveillance Program. MBL is a pre-cancerous blood condition where there are CLL-like cells in the blood but not enough of them to diagnosis CLL. People with MBL are at risk for getting CLL and require active monitoring. […] Our team closely monitors you for any changes or symptoms that suggest the CLL is getting worse. Signs can include: More leukemia cells, Fewer red blood cells and platelets, Changes in the size of lymph nodes, Changes in the size of the spleen or liver. […] A high white blood cell count does not always mean you have to start treatment. Your care team will recommend a monitoring plan thats right for you. Theyll let you know if you should stop active surveillance and meet with your leukemia doctor sooner.

• #24 Key Statistics for Chronic Lymphocytic Leukemia

  https://www.healthline.com/health/cll/statistics-and-facts

  People with CLL are more likely to develop a second cancer than people without CLL. Compared with the larger U.S. population, people with CLL are 20% more likely to develop a second type of cancer independent of their CLL. […] As treatment for CLL has improved, so too have survival rates. From 2012 to 2018, the 5-year relative survival rate of people with CLL compared with those without CLL was 88%. […] Older data suggests more than 70% of people with CLL live for at least 10 years after diagnosis. These estimates are likely to be higher in more recent years. […] In people with high risk features of CLL, including older age (over 65 years), more advanced disease, or certain molecular markers, the most common cause of death is likely to be disease progression or complications related to CLL.

• #25 Chronic lymphocytic leukemia life expectancy and survival rates

  https://www.medicalnewstoday.com/articles/322756

  The 5-year relative survival rate for chronic lymphocytic leukemia (CLL) among adults ages 20 or older is 87%. […] CLL accounts for around 38% of new leukemia cases in adults ages 20 years or older. […] Survival rates for leukemia have improved significantly over the past 40 years. […] The stage of CLL is an important factor in life expectancy. […] A higher stage number means that CLL is impacting more of the body. A higher stage will often shorten a person’s life expectancy. […] Other factors that can affect survival rates include: whether CLL has come back or improved with treatment, how cancer cells have spread in the bone marrow, a person’s general health, the level of bone marrow involvement, whether there is a high level of cells containing the proteins ZAP-70 or CD38, whether the TP53 gene is absent from cells. […] Although there is no cure for CLL, ongoing treatment may help a person live with the condition for a long time. […] Currently, around 87% of people ages 20 or older with CLL survive for at least 5 years following diagnosis.

• #26 Active Surveillance For Chronic Lymphocytic Leukemia (CLL)

  https://snconnect.survivornet.com/latest-news/active-surveillance-for-chronic-lymphocytic-leukemia-cll/

  CLL patients can live for years without any symptoms or needing treatment. In fact, a small number of these patients, such as those with del13q14 but no other genetic mutations, may enjoy the same life expectancy without any treatment as those who do not have CLL. […] There has been no robust scientific evidence to date that early treatment for people with early, low-risk CLL holds any tangible benefit for or prolongs the lifespan of patients. […] Immunosuppression can put CLL patients at an increased risk for developing second cancers compared to the average population. Thus, they need to be prompt and diligent about cancer screenings.

• #27 Active Surveillance For Chronic Lymphocytic Leukemia (CLL) | SurvivorNet Connect

  https://snconnect.survivornet.com/articles/active-surveillance-for-chronic-lymphocytic-leukemia-cll/

  CLL patients can live for years without any symptoms or needing treatment. In fact, a small number of these patients, such as those with del13q14 but no other genetic mutations, may enjoy the same life expectancy without any treatment as those who do not have CLL. […] There has been no robust scientific evidence to date that early treatment for people with early, low-risk CLL holds any tangible benefit for or prolongs the lifespan of patients. […] Immunosuppression can put CLL patients at an increased risk for developing second cancers compared to the average population. Thus, they need to be prompt and diligent about cancer screenings.

• #28 Active surveillance for chronic lymphocytic leukemia | Canadian Cancer Society

  https://cancer.ca/en/cancer-information/cancer-types/chronic-lymphocytic-leukemia-cll/treatment/active-surveillance

  CLL affects the immune system. So when you have CLL, you’re at an increased risk for other cancers. […] Non-melanoma skin cancer is the most common second cancer diagnosed in people with CLL. […] It’s also important to follow screening guidelines for breast, cervical and colorectal cancer in your province or territory. […] Knowing that you have CLL but that you won’t start active treatment right away may make you feel anxious or worried. […] Your mental health is important.

• #29 ASCO 2022: Racial and Socioeconomic Disparities among Patients with Chronic Lymphocytic Leukemia: Analysis of Surveillance, Epidemiology, and End Results Program Data – CLL Society

  https://cllsociety.org/2022/10/asco-2022-racial-and-socioeconomic-disparities-among-patients-with-chronic-lymphocytic-leukemia-analysis-of-surveillance-epidemiology-and-end-results-program-data/

  ASCO 2022: Racial and Socioeconomic Disparities among Patients with Chronic Lymphocytic Leukemia: Analysis of Surveillance, Epidemiology, and End Results Program Data […] Being American Indian/Alaska Native and Black were independent prognostic variables for having shorter overall survival (OS). At the same time, higher socioeconomic status (SES) was found to be significantly and independently associated with living longer. […] The team at Ohio State University Comprehensive Cancer Center used Surveillance, Epidemiology, and End Results (SEER) data to determine how race and socioeconomic status (SES) affect survival for those with CLL. SEER is a free resource of the NIH, specifically the National Cancer Institute (NCI), and is “an authoritative source for cancer statistics in the United States.”

• #30 ASCO 2022: Racial and Socioeconomic Disparities among Patients with Chronic Lymphocytic Leukemia: Analysis of Surveillance, Epidemiology, and End Results Program Data – CLL Society

  https://cllsociety.org/2022/10/asco-2022-racial-and-socioeconomic-disparities-among-patients-with-chronic-lymphocytic-leukemia-analysis-of-surveillance-epidemiology-and-end-results-program-data/

  Black race and low socioeconomic status (SES) are prognostic of shorter overall survival in CLL. However, further research is needed to determine whether this is due to access to therapy, quality of care, social determinants of health, or disease biology. […] CLL Society is working with Mayo Clinic on a trial as to why this might be. Is it something about the disease itself in blacks, or is the answer more environmental, or is it about treatment choices? We simply don’t know, but if you are from an underrepresented minority, please consider helping us get the answers by enrolling in the free trial: The Genetics of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL / SLL) in African Americans and Other Minorities. […] CLL Society to committed to increasing awareness of these persistent disparities and searching for ways to improve outcomes for all.

• #31 Cancer Incidence – Chronic Lymphocytic Leukemia

  https://nmtracking.doh.nm.gov/dataportal/indicator/summary/CancerIncidChrLymLeukemia.html

  Chronic lymphocytic leukemia accounts for 15% of all leukemias in adults. Each year, chronic lymphocytic leukemia accounts for just over 1% of all new cancer cases and less than 1% of all cancer deaths in the U.S. This equates to 20,160 cases and 4,410 deaths annually. The five-year survival rate is 88%. […] New Mexico has averaged 117 new cases of chronic lymphocytic leukemia each year between 2017 and 2021. […] Nationally, chronic lymphocytic leukemia is more common among men than women, particularly white men. In contrast, the Asian/Pacific Islander population in New Mexico had the highest incidence with 6.2 cases per 100,000 population. Overall the incidence is lower in New Mexico than nationally (4.2 vs 4.7 per 100,000, respectively).

• #32 Chronic lymphocytic leukemia statistics | Canadian Cancer Society

  https://cancer.ca/en/cancer-information/cancer-types/chronic-lymphocytic-leukemia-cll/statistics

  It can take several years to collect and confirm cancer data, so the number of new cancer cases (incidence) and deaths (mortality) from recent years may not be available for some time. The most recent incidence statistics for chronic lymphocytic leukemia (CLL) are from 2019: 1,700 Canadians were diagnosed with CLL. 1,095 men were diagnosed with CLL. 605 women were diagnosed with CLL. The most recent mortality statistics for CLL are from 2022: 555 Canadians died from CLL. 358 men died from CLL. 197 women died from CLL.

• #33 Detailing the epidemiological and clinical characteristics of chronic lymphocytic leukaemia in Portugal—Results from a population-based cancer registry cohort study | PLOS One

  https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0258423

  Chronic lymphocytic leukaemia (CLL) is the most common leukaemia among adults in western countries. Considering the increasing incidence and prevalence of this condition, it is highly relevant to better characterise these patients in Portugal, where data is still scarce. […] A total of 496 patients were included and median follow-up time was 5.46 years. Crude incidence rates were 5.03 and 5.22 per 100,000 inhabitants for 2013 and 2014, respectively, and age-adjusted incidence rates were 3.18:100,000 European population for 2013 and 3.35:100,000 European population for 2014. […] Incidence, clinical presentation and survival of CLL Portuguese patients are similar to those reported for other western countries. The increased risk of second malignancies raises concerns and needs adequate clinical watchfulness.

• #34 Chronic lymphocytic leukaemia (CLL) – Leukaemia Foundation

  https://www.leukaemia.org.au/blood-cancer/types-of-blood-cancer/leukaemia/chronic-lymphocytic-leukaemia/

  Chronic lymphocytic leukaemia (CLL) is a type of slow-growing leukaemia that affects developing B-lymphocytes. B lymphocytes (also known as B-cells) are specialised white blood cells. Under normal conditions they produce immunoglobulins (also called antibodies) that help protect our bodies against infection and disease. In people with CLL, lymphocytes undergo a malignant (cancerous) change and become leukaemic cells. […] Each year in Australia around 1000 people are diagnosed with CLL. While CLL is a relatively uncommon type of cancer, it is the most common type of leukaemia diagnosed in Australia. […] The risk of developing CLL increases with age. Almost 80% of all new cases are diagnosed in people who are over the age of 60. CLL is rare in people under 40 and occurs more frequently in men than in women.

• #35

  https://link.springer.com/article/10.1007/s12185-024-03832-x

  Venetoclax was approved for relapsed/refractory chronic lymphocytic leukemia (R/R CLL) and small lymphocytic leukemia (SLL) in Japan in September 2019; however, clinical data in Japanese patients are limited. This all-case post-marketing surveillance assessed efficacy and safety in Japanese patients with R/R CLL/SLL who started venetoclax treatment between November 2019 and August 2020. Overall, the safety and efficacy analysis sets included 129 and 114 patients, respectively. The overall response rate (ORR) was 57.0%; ORRs were higher in patients with versus without concomitant rituximab (65.4% vs. 54.7%), and in patients with 1 versus 2 prior lines of therapies (72.5% vs. 44.4%). Adverse events (AEs) were reported in 66.7% of patients (86/129); the most common AEs were neutrophil count decreased (22.5%), white blood cell count decreased (7.8%), and tumor lysis syndrome (TLS; 6.2%). AEs of special interest (TLS, myelosuppression, and infection) were manageable in clinical practice in Japan. Venetoclax is efficacious and safe for R/R CLL/SLL patients in the real-world setting in Japan.

• #36 The global burden and attributable risk factors of chronic lymphocytic leukemia in 204 countries and territories from 1990 to 2019: analysis based on the global burden of disease study 2019 | BioMedical Engineering OnLine | Full Text

  https://biomedical-engineering-online.biomedcentral.com/articles/10.1186/s12938-021-00973-6

  The disease tended to occur in males, the elderly populations, and people living in high-SDI regions. What cannot be ignored is the rapid growth of the disease burden in middle-SDI regions, which potentially indicated an underestimated incidence and mortality in underdeveloped countries. In addition, of attributable risk factors, smoking presented as the most contributed across the globe, with potential risk of carcinogen exposure containing a prominent issue in low-SDI regions which needs further investigation.

• #37 Chronic Lymphocytic Leukemia: Epidemiology Forecast to 2027

  https://www.researchandmarkets.com/reports/4720294/chronic-lymphocytic-leukemia-epidemiology?srsltid=AfmBOopq2nnx_H4yx_q81TkHyi0ZboGn_TQt549no82jI7-8jO1bASrX

  Chronic lymphocytic leukemia (CLL) (International Statistical Classification of Diseases and Related Health Problems, 10th Revision [ICD-10] code = C91.1), also known as chronic lymphoid leukemia, is a type of cancer of the white blood cells (lymphocytes). CLL affects a particular lymphocyte, the B cell, which accumulates mainly in the bone marrow and blood, and normally fights infection. […] Epidemiologists utilized national databases and robust peer-reviewed journal articles to build the CLL diagnosed incident and diagnosed prevalent cases forecast for the 7MM. […] The diagnosed incident cases of CLL in the 7MM will increase from 41,974 cases in 2017 to 50,474 cases in 2027, at an Annual Growth Rate (AGR) of 2.03% over the forecast period. […] Epidemiologists attribute the growth in the diagnosed incident cases of CLL in the 7MM to the moderately rising trend in incidence in the 7MM, combined with the changing population demographics in the respective markets.

• #38 Chronic Lymphocytic Leukemia: Epidemiology Forecast to 2027

  https://www.globaldata.com/store/report/chronic-lymphocytic-leukemia-epidemiology-forecast-to-2027/

  Chronic lymphocytic leukemia (CLL) (International Statistical Classification of Diseases and Related Health Problems, 10th Revision [ICD-10] code = C91.1), also known as chronic lymphoid leukemia, is a type of cancer of the white blood cells (lymphocytes). CLL affects a particular lymphocyte, the B cell, which accumulates mainly in the bone marrow and blood, and normally fights infection. […] GlobalData epidemiologists utilized national databases and robust peer-reviewed journal articles to build the CLL diagnosed incident and diagnosed prevalent cases forecast for the 7MM. The disease definition for CLL was consistent with the ICD-10 code C91.1. Whenever available, country-specific sources were utilized. In cases of data scarcity, appropriate proxies were used to fill the data gaps. […] The diagnosed incident cases of CLL in the 7MM will increase from 41,974 cases in 2017 to 50,474 cases in 2027, at an Annual Growth Rate (AGR) of 2.03% over the forecast period. For the majority of the forecast period, the US will have the highest number of diagnosed incident cases of CLL. GlobalData epidemiologists attribute the growth in the diagnosed incident cases of CLL in the 7MM to the moderately rising trend in incidence in the 7MM, combined with the changing population demographics in the respective markets.

• #39 Fixed-duration Calquence-based regimens recommended for approval in the EU by CHMP for 1st-line chronic lymphocytic leukaemia

  https://www.astrazeneca.com/media-centre/press-releases/2025/fixed-duration-calquence-recommended-in-eu-for-cll.html

  Chronic lymphocytic leukaemia is an incurable cancer which means patients live with the disease and stay on treatment for many years, which can have long-term effects. […] CLL is the most common type of leukaemia in adults, with an estimated 27,000 patients diagnosed in the UK, France, Germany, Spain and Italy in 2024. […] Chronic lymphocytic leukaemia (CLL) is the most prevalent type of leukaemia in adults, with over 117,000 new cases globally in 2021. […] In CLL, there is an accumulation of abnormal lymphocytes within the blood, bone marrow and lymph nodes. […] The AMPLIFY trial enrolled patients from 2019 to 2021, continuing through the COVID-19 pandemic. […] Patients with blood cancer remain at a disproportionately high risk of severe outcomes from COVID-19, including hospitalisation and death compared to the general population.

• #40 Chronic Lymphocytic Leukemia: 2025 Update on the Epidemiology, Pathogenesis, Diagnosis, and Therapy – PubMed

  https://pubmed.ncbi.nlm.nih.gov/39871707/

  Chronic lymphocytic leukemia (CLL) is the most frequent type of leukemia. It typically occurs in older patients and has a highly variable clinical course. […] The CLL international prognostic index (CLL-IPI) integrates genetic, biological, and clinical variables to identify distinct risk groups of patients with CLL. […] The author declares institutional research support by Abbvie, AstraZeneca, Beigene, Lilly, and Roche. […] The Surveillance E, and End Results (SEER) Program of the National Cancer Institute, Cancer Stat Facts: Leukemia Chronic Lymphocytic Leukemia (CLL) (2024).

• #41 Overview of the Recent Developments in Chronic Lymphocytic Leukemia, Part 1

  https://jhoponline.com/issue-archive/2016-issues/jhop-june-2016-vol-6-no-2/16799:overview-of-the-recent-developments-in-chronic-lymphocytic-leukemia-part-1

  CLL is the most common leukemia in Western countries, representing approximately 22% to 30% of all leukemias worldwide. […] The global annual incidence is between 1 and 5.5 per 100,000 people, and more men than women are affected. […] The incidence of CLL is approximately 4.2 cases per 100,000 people in the Western world. […] This figure also shows that few countries have a large population with CLL, which brings to light potential challenges that arise when selecting countries and sites for studying CLL, especially in phase 3 trials. […] In addition to the low incidence/prevalence, there is intense competition for these patients.

Zobacz więcej